{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T09:19:16Z","timestamp":1774084756729,"version":"3.50.1"},"reference-count":46,"publisher":"Impact Journals, LLC","issue":"39","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2016,9,27]]},"DOI":"10.18632\/oncotarget.11379","type":"journal-article","created":{"date-parts":[[2016,8,19]],"date-time":"2016-08-19T03:54:52Z","timestamp":1471578892000},"page":"62989-63002","source":"Crossref","is-referenced-by-count":20,"title":["Molecular dissection of the valproic acid effects on glioma cells"],"prefix":"10.18632","volume":"7","author":[{"given":"Sabine","family":"Hoja","sequence":"first","affiliation":[{"name":"Department of Neuropathology, Regensburg University Hospital, Regensburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Schulze","sequence":"additional","affiliation":[{"name":"Department of Neuropathology, Regensburg University Hospital, Regensburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Rehli","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III, Regensburg University Hospital, Regensburg, Germany"},{"name":"RCI Regensburg Centre for Interventional Immunology, Regensburg University Hospital, Regensburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Proescholdt","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Regensburg University Hospital, Regensburg, Germany"},{"name":"Wilhelm Sander Neuro-Oncology Unit, Regensburg University Hospital, Regensburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christel","family":"Herold-Mende","sequence":"additional","affiliation":[{"name":"Experimental Neurosurgery, Department of Neurosurgery, University of Heidelberg, Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Hau","sequence":"additional","affiliation":[{"name":"Wilhelm Sander Neuro-Oncology Unit, Regensburg University Hospital, Regensburg, Germany"},{"name":"Department of Neurology, Regensburg University, Regensburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus J.","family":"Riemenschneider","sequence":"additional","affiliation":[{"name":"Department of Neuropathology, Regensburg University Hospital, Regensburg, Germany"},{"name":"Wilhelm Sander Neuro-Oncology Unit, Regensburg University Hospital, Regensburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2016,8,18]]},"reference":[{"issue":"10","key":"1","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Lacombe","year":"2005","journal-title":"N Engl J Med"},{"issue":"5","key":"2","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.mehy.2012.07.037","article-title":"Gliomas and seizures","volume":"79","author":"Musto","year":"2012","journal-title":"Med Hypotheses"},{"issue":"3","key":"3","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.ijrobp.2013.02.012","article-title":"Valproic acid use during radiation therapy for glioblastoma associated with improved survival","volume":"86","author":"Chan","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7","key":"4","doi-asserted-by":"crossref","first-page":"556","DOI":"10.3109\/08880018.2011.563774","article-title":"Potential role for valproate in the treatment of high--risk brain tumors of childhood-results from a retrospective observational cohort study","volume":"28","author":"Fontenele","year":"2011","journal-title":"Pediatr Hematol Oncol"},{"issue":"7","key":"5","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1093\/neuonc\/not057","article-title":"Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme","volume":"15","author":"Vecht","year":"2013","journal-title":"Neuro Oncol"},{"issue":"3","key":"6","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s11060-004-2338-2","article-title":"P450 enzyme inducing and non-enzyme inducing antiepileptics in glioblastoma patients treated with standard chemotherapy","volume":"72","author":"Grisold","year":"2005","journal-title":"J Neurooncol"},{"issue":"12","key":"7","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1212\/WNL.0b013e31822f02e1","article-title":"Prolonged survival with valproic acid use in the EORTC\/NCIC temozolomide trial for glioblastoma","volume":"77","author":"Stupp","year":"2011","journal-title":"Neurology"},{"issue":"5","key":"8","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.ijrobp.2015.04.038","article-title":"A Phase 2 Study of Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients With Glioblastoma","volume":"92","author":"Camphausen","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"9","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s11060-016-2054-8","article-title":"Valproic acid, compared to other antiepileptic drugs, is associated with improved overall and progression-free survival in glioblastoma but worse outcome in grade II\/III gliomas treated with temozolomide","volume":"127","author":"Nahed","year":"2016","journal-title":"J Neurooncol"},{"issue":"24","key":"10","doi-asserted-by":"crossref","first-page":"6969","DOI":"10.1093\/emboj\/20.24.6969","article-title":"Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells","volume":"20","author":"Heinzel","year":"2001","journal-title":"EMBO J"},{"issue":"3","key":"11","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/35106079","article-title":"Histone deacetylases and cancer: causes and therapies","volume":"1","author":"Kelly","year":"2001","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"12","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s12031-014-0329-0","article-title":"The effects of histone deacetylase inhibitors on glioblastoma-derived stem cells","volume":"55","author":"Sugaya","year":"2015","journal-title":"J Mol Neurosci"},{"issue":"2","key":"13","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s11060-014-1713-x","article-title":"The effect of valproic acid in combination with irradiation and temozolomide on primary human glioblastoma cells","volume":"122","author":"Martin","year":"2015","journal-title":"J Neurooncol"},{"key":"14","first-page":"987495","article-title":"Valproic acid downregulates the expression of MGMT and sensitizes temozolomide-resistant glioma cells","volume":"2012","author":"Jeun","year":"2012","journal-title":"J Biomed Biotechnol"},{"issue":"1","key":"15","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11060-011-0725-z","article-title":"Valproic acid sensitizes human glioma cells for temozolomide and gamma-radiation","volume":"107","author":"Stalpers","year":"2012","journal-title":"J Neurooncol"},{"issue":"32","key":"16","doi-asserted-by":"crossref","first-page":"5459","DOI":"10.1200\/JCO.2009.22.1291","article-title":"Histone deacetylase inhibitors in cancer therapy","volume":"27","author":"Chabner","year":"2009","journal-title":"J Clin Oncol"},{"key":"17","article-title":"Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma","author":"Weller","year":"2016","journal-title":"J Clin Oncol"},{"issue":"7","key":"18","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1093\/neuonc\/not095","article-title":"Are we ready for a randomized trial of valproic acid in newly diagnosed glioblastoma?","volume":"15","author":"Weller","year":"2013","journal-title":"Neuro Oncol"},{"issue":"10","key":"19","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1101\/gr.7.10.986","article-title":"The significance of digital gene expression profiles","volume":"7","author":"Claverie","year":"1997","journal-title":"Genome Res"},{"key":"20","first-page":"186","article-title":"Complex DNA repair pathways as possible therapeutic targets to overcome temozolomide resistance in glioblastoma","volume":"2","author":"Sasaki","year":"2012","journal-title":"Front Oncol"},{"issue":"1","key":"21","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ccr.2009.12.020","article-title":"Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1","volume":"17","author":"Gabriel","year":"2010","journal-title":"Cancer Cell"},{"issue":"8","key":"22","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nrd4626","article-title":"SLC transporters as therapeutic targets: emerging opportunities","volume":"14","author":"Giacomini","year":"2015","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"23","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1517\/17425255.2015.1028356","article-title":"Influence of multidrug resistance and drug transport proteins on chemotherapy drug metabolism","volume":"11","author":"Larkin","year":"2015","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"10","key":"24","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1517\/17425240903167942","article-title":"New strategies to deliver anticancer drugs to brain tumors","volume":"6","author":"Trapani","year":"2009","journal-title":"Expert Opin Drug Deliv"},{"issue":"2","key":"25","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1634\/theoncologist.5-2-144","article-title":"Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma","volume":"5","author":"Kirkwood","year":"2000","journal-title":"Oncologist"},{"key":"26","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.mrgentox.2015.06.001","article-title":"APE1\/REF-1 down-regulation enhances the cytotoxic effects of temozolomide in a resistant glioblastoma cell line","volume":"793","author":"Sakamoto-Hojo","year":"2015","journal-title":"Mutat Res Genet Toxicol Environ Mutagen"},{"issue":"1","key":"27","doi-asserted-by":"crossref","first-page":"102","DOI":"10.2174\/1874467211205010102","article-title":"Temozolomide: mechanisms of action, repair and resistance","volume":"5","author":"Bradshaw","year":"2012","journal-title":"Curr Mol Pharmacol"},{"issue":"7","key":"28","doi-asserted-by":"crossref","first-page":"520","DOI":"10.2174\/187152010793498627","article-title":"Overcoming resistance of glioblastoma to conventional cytotoxic therapies by the addition of PARP inhibitors","volume":"10","author":"Chalmers","year":"2010","journal-title":"Anticancer Agents Med Chem"},{"issue":"3","key":"29","doi-asserted-by":"crossref","first-page":"218","DOI":"10.2174\/156800912799277403","article-title":"Targeted therapy for brain tumours: role of PARP inhibitors","volume":"12","author":"Tentori","year":"2012","journal-title":"Curr Cancer Drug Targets"},{"issue":"5","key":"30","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1124\/mol.110.066076","article-title":"Nijmegen breakage syndrome protein (NBN) causes resistance to methylating anticancer drugs such as temozolomide","volume":"78","author":"Kaina","year":"2010","journal-title":"Mol Pharmacol"},{"key":"31","article-title":"Endoplasmic reticulum stress-inducing drugs sensitize glioma cells to temozolomide through downregulation of MGMT, MPG, and Rad51","author":"Alonso","year":"2016","journal-title":"Neuro Oncol"},{"issue":"15","key":"32","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1158\/0008-5472.CAN-14-3616","article-title":"Minor Changes in Expression of the Mismatch Repair Protein MSH2 Exert a Major Impact on Glioblastoma Response to Temozolomide","volume":"75","author":"Samson","year":"2015","journal-title":"Cancer Res"},{"issue":"14","key":"33","doi-asserted-by":"crossref","first-page":"4622","DOI":"10.1158\/1078-0432.CCR-08-3012","article-title":"MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance","volume":"15","author":"Louis","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"2","key":"34","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s11060-007-9402-7","article-title":"Valproic acid induces p21 and topoisomerase-II (alpha\/beta) expression and synergistically enhances etoposide cytotoxicity in human glioblastoma cell lines","volume":"85","author":"Gopalakrishnan","year":"2007","journal-title":"J Neurooncol"},{"issue":"2","key":"35","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/neuonc\/not164","article-title":"MiR-328 promotes glioma cell invasion via SFRP1-dependent Wnt-signaling activation","volume":"16","author":"Riemenschneider","year":"2014","journal-title":"Neuro Oncol"},{"key":"36","volume-title":"Temodar (temozolomide)","author":"Prescribing information","year":"2007"},{"issue":"1","key":"37","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/path.4366","article-title":"Aberrant self-renewal and quiescence contribute to the aggressiveness of glioblastoma","volume":"234","author":"Herold-Mende","year":"2014","journal-title":"J Pathol"},{"issue":"6","key":"38","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1089\/cell.2013.0018","article-title":"Effect of histone deacetylase inhibitor valproic acid treatment on donor cell growth characteristics, cell cycle arrest, apoptosis, and handmade cloned bovine embryo production efficiency","volume":"15","author":"Madan","year":"2013","journal-title":"Cell Reprogram"},{"issue":"1","key":"39","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1750-3639.2011.00507.x","article-title":"DNA hypermethylation and histone modifications downregulate the candidate tumor suppressor gene RRP22 on 22q12 in human gliomas","volume":"22","author":"Riemenschneider","year":"2012","journal-title":"Brain Pathol"},{"issue":"11","key":"40","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1002\/ijc.23409","article-title":"Frequent biallelic inactivation and transcriptional silencing of the DIRAS3 gene at 1p31 in oligodendroglial tumors with 1p loss","volume":"122","author":"Reifenberger","year":"2008","journal-title":"Int J Cancer"},{"issue":"2","key":"41","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1006\/geno.1996.0197","article-title":"GenomeInspector: basic software tools for analysis of spatial correlations between genomic structures within megabase sequences","volume":"33","author":"Werner","year":"1996","journal-title":"Genomics"},{"issue":"1","key":"42","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/nprot.2008.211","article-title":"Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources","volume":"4","author":"Lempicki","year":"2009","journal-title":"Nat Protoc"},{"key":"43","doi-asserted-by":"crossref","first-page":"20","DOI":"10.4103\/1477-3163.120632","article-title":"O-6-methylguanine-deoxyribonucleic acid methyltransferase methylation enhances response to temozolomide treatment in esophageal cancer","volume":"12","author":"Salgia","year":"2013","journal-title":"J Carcinog"},{"issue":"2","key":"44","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s11033-013-2908-5","article-title":"Chemotherapeutic resistance in anaplastic astrocytoma cell lines treated with a temozolomide-lomeguatrib combination","volume":"41","author":"Sunguroglu","year":"2014","journal-title":"Mol Biol Rep"},{"issue":"12","key":"45","doi-asserted-by":"crossref","first-page":"12327","DOI":"10.1007\/s13277-014-2545-1","article-title":"Annexin A5 promotes invasion and chemoresistance to temozolomide in glioblastoma multiforme cells","volume":"35","author":"Zhu","year":"2014","journal-title":"Tumour Biol"},{"issue":"2","key":"46","first-page":"171","article-title":"[Molecular diagnostics in neuropathology [Article in German]","volume":"36","author":"Riemenschneider","year":"2015","journal-title":"Pathologe"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.11379","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T11:48:31Z","timestamp":1589284111000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.11379"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,18]]},"references-count":46,"journal-issue":{"issue":"39","published-print":{"date-parts":[[2016,9,27]]}},"alternative-id":["11379","27556305"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.11379","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,18]]}}}